Alfuzosin

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

BPH/LUTS/Sexual Functions

Conditions

BPH/LUTS/Sexual Functions

Trial Timeline

Mar 1, 2004 → Dec 1, 2004

NCT ID

NCT00542165

About Alfuzosin

Alfuzosin is a approved stage product being developed by Sanofi for BPH/LUTS/Sexual Functions. The current trial status is completed. This product is registered under clinical trial identifier NCT00542165. Target conditions include BPH/LUTS/Sexual Functions.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00576823	Phase 3	Completed	Dec 1, 2007	Oct 1, 2009	Hydronephrosis
NCT00688948	Phase 2/3	Terminated	Nov 1, 2007	Nov 1, 2009	Multiple Sclerosis
NCT00399464	Phase 3	Completed	Nov 1, 2006	Oct 1, 2007	Prostatic Hyperplasia
NCT00454402	Phase 3	Terminated	Aug 1, 2006	Jul 1, 2007	Prostatic Hyperplasia
NCT00401661	Approved	Completed	Jun 1, 2006	—	Prostatic Hyperplasia
NCT00486785	Approved	Completed	Apr 1, 2006	Mar 1, 2008	Prostatic Hyperplasia
NCT00280605	Approved	Completed	Aug 1, 2005	Feb 1, 2006	Prostatic Hyperplasia
NCT00453908	Phase 3	Terminated	May 1, 2004	—	Urinary Retention
NCT00542165	Approved	Completed	Mar 1, 2004	Dec 1, 2004	BPH/LUTS/Sexual Functions
NCT00637715	Approved	Completed	Oct 1, 2003	Dec 1, 2004	Benign Prostatic Hyperplasia
NCT00575913	Approved	Completed	Sep 1, 2003	Mar 1, 2005	Prostatic Diseases
NCT00540891	Phase 3	Completed	Feb 1, 2003	Oct 1, 2004	Benign Prostatic Hyperplasia
NCT00290030	Phase 3	Completed	May 1, 2001	Oct 1, 2004	Prostatic Hyperplasia